Income StatementBalance SheetCash FlowSegments
ResMed logo

ResMed Cash Flow Statement

Operating, investing, and financing cash movements

ResMed generated $1.9B in operating cash flow over the trailing twelve months. After $135.7M in capital expenditures, free cash flow was $1.8B. Free cash flow increased 0.1% year-over-year. Based on the Q1 2026 filing.

Net Cash From Operating (TTM)$1.9BNet Cash From Investing (TTM)-$295.3MNet Cash From Financing (TTM)-$907.8MCapital Expenditures (TTM)$135.7MDepreciation And Amortization Cf (TTM)$220.2MNet Change In Cash (TTM)$727.8M
Latest FilingQ1 2026
Report Date2026-04-30
Market Cap$29.6B
P/E Ratio19.49
ROE25.25%

Investing

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Acquisitions, net of cash acquired$670.0K$0.0$138.6M$522.0K$0.0$24.9M
Capital expenditures$20.6M$20.8M$30.6M$43.0M$28.5M$33.7M
Proceeds from disposition of marketable securities and other investments$250.0K$0.0$250.0K$0.0$250.0K$2.5M
Net cash from investing activities-$36.7M-$31.8M-$133.7M-$52.6M-$50.9M-$58.0M
Proceeds from maturities/sales of investments$250.0K$0.0$250.0K$0.0$250.0K$2.5M
Purchases of intangible assets$2.8M$3.0M$3.2M$2.8M-$1.3M$0.0
Purchases of investments$1.0M$2.1M$2.0M$2.2M$4.2M$20.1M
Payments for (Proceeds from) Derivative Instruments, Investing$11.8M$5.9M-$40.4M$4.1M$12.4M-$24.1M

Operating

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Change in accounts payable$4.2M$63.1M$49.1M$7.6M$10.6M$103.9M
Change in accounts receivable$67.9M$40.0M$5.2M-$30.0M$72.7M$16.9M
Change in inventories$7.6M-$29.9M$32.1M$14.7M-$26.1M-$12.5M
Change in other assets$43.6M-$79.4M-$47.0M-$2.3M$106.4M$48.3M
Depreciation and amortization$46.4M$43.7M$63.6M$47.7M$49.9M$59.0M
Equity in income of investees$1.1M$335.0K—$1.5M$1.5M$1.7M
Distributions from equity method investments$911.0K$911.0K$911.0K———
Net gains (losses) on investments-$1.4M-$5.6M-$2.5M-$6.2M$306.0K-$10.1M
Net cash from operating activities$308.6M$578.7M$538.8M$457.3M$339.7M$554.1M
Net income$344.6M$365.0M$379.7M$348.5M$392.6M$398.7M
Income Loss From Equity Method Investments Net Of Dividends Or Distributions$911.0K$911.0K$911.0K———
Insurance Recoveries$0.0$0.0$0.0———
Non-cash operating lease expense$9.5M$8.2M$10.7M$10.0M$12.4M$10.1M
Operating lease right-of-use asset amortization$9.5M$8.2M$10.7M$10.0M$12.4M$10.1M
Stock-based compensation$22.6M$24.1M$24.8M$21.2M$28.9M$26.8M

Financing

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Repayments of debt$5.0M$0.0$5.0M$0.0$5.0M$0.0
Dividends paid$77.7M$77.7M$77.6M$87.8M$87.6M$87.2M
Acquisition Of Consolidated Subsidiary, Financing Activities$2.7M$2.7M$2.7M———
Net cash from financing activities-$147.5M-$144.1M-$163.9M-$230.3M-$258.3M-$255.2M
Proceeds from issuance of common stock$26.9M$9.0M$30.2M$8.2M$29.6M$7.4M
Repurchases of common stock$75.0M$75.0M$100.0M$150.0M$175.0M$175.0M
Taxes paid for net share settlement$16.7M$364.0K$590.0K$719.0K$20.3M$418.0K

Free Cash Flow

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Free cash flow$288.0M$557.9M$508.2M$414.4M$311.2M$520.5M

Other

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Effect of exchange rate changes on cash-$28.8M$8.0M$35.6M-$71.0K$2.8M$2.6M
Net increase (decrease) in cash$95.6M$410.8M$276.7M$174.4M$33.2M$243.4M
Restructuring Reserve Settled Without Cash2$0.0$0.0$0.0———

Supplemental

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Income taxes paid$118.6M-$26.5M$16.2M$61.9M$147.5M$71.7M
Interest paid-$66.0K$14.2M$6.9M$6.9M$6.6M$6.5M
Non-cash Acquisition, Liabilities Assumed$0.0$0.0$6.3M———
Business Acquisition, Contingent Consideration, Recognized Liability-$670.0K$3.1M—$0.0$0.0-$3.2M
Deferred payments$0.0$0.0————
Goodwill on acquisition$0.0$0.0$101.3M$1.3M$0.0$18.9M
Fair value of assets acquired, excluding cash$0.0$0.0$43.5M-$798.0K$0.0$15.6M